# Artbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artbio

- Industry: Biotechnology
- Headquarters: Cheshire, UK
- Website: www.artbio.com
- Total disclosed funding: $245M
- Latest round: Series B (Jul 5, 2025)
- Investors on record: 7

## About

Based in the UK, Artbio Limited operates as a biopharmaceutical company focusing on the development of innovative alpha radioligand therapies aimed at enhancing cancer treatment efficacy and safety.Founded in 2021 and headquartered in Cheshire, UK, Artbio Limited specializes in developing targeted radioligand therapies. The company has raised a total of USD 132.00 mn in its latest funding round, Series B, which occurred on 5th July 2025. The funding was co-led by investors including Alexandria Venture Investments, B Capital Group, and F-Prime Capital, among others. The founder, Anders Tuv, has a significant background in the biopharmaceutical industry, contributing to the company's strategic direction and growth.ARTBIO specializes in the development of a new class of alpha radioligand therapies (ART) aimed at enhancing cancer treatment efficacy and safety. The company's core offerings focus on targeted radioligand therapies that leverage high-affinity and selective drug molecules to effectively eradicate tumors while minimizing damage to healthy tissues. ARTBIO's lead program, AB001, has advanced into first-in-human studies, with additional programs targeting multiple solid tumors also in various stages of development. The company's products are designed for use in oncology, primarily targeting healthcare providers, including hospitals and cancer treatment centers across the United States and Europe.ARTBIO's revenue is primarily generated through collaborations with healthcare providers and institutions that utilize their alpha radioligand therapies in cancer treatment. The company adopts a business-to-business (B2B) model, facilitating transactions directly with medical facilities and pharmaceutical partners. Revenue is derived from contracts related to clinical trials, product sales, and potential licensing agreements for their proprietary therapies, such as AB001. The company's business structure is aligned with industry standards for pharmaceutical products, which typically involve negotiated pricing based on treatment regimens rather than direct consumer sales.In July 2025, Artbio Limited raised USD 132.00 mn in Series B funding, which will be utilized to accelerate its phase 2 clinical trials and support ongoing research and development programs. The company is focused on expanding its portfolio with new alpha radioligand therapies targeting various cancers and intends to enter new markets, particularly in Europe and North America, by 2026. Through strategic partnerships and advancements in clinical trials, ARTBIO aims to enhance its market presence in the oncology field.

## Funding rounds

- Series B, Jul 5, 2025, $132M — Sofinnova Investments, Alexandria Venture Investments, F-Prime Capital, Third Rock Ventures, Qatar Investment Authority, Omega Funds, B Capital
- Series A, Dec 7, 2023, $90M — F-Prime Capital, Third Rock Ventures, Omega Funds
- Seed, Jun 21, 2023, $23M — F-Prime Capital, Omega Funds

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Seed, Series A, Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Seed, Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B
- B Capital (https://capitalatlas.ai/funds/b-capital) — Series B